{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T20:51:07Z","timestamp":1790455867995,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Nongenetic transcription evolution has been increasingly explored and recognized to drive tumor cell progression and therapeutic resistance. As the regulation hub of transcription machinery, cyclin-dependent kinase 9 (CDK9) is the gatekeeper of RNA polymerase II transcription, and CDK9 dysfunction results in transcriptomic reprogramming and tumor cell progression. We recently reported that the heat shock protein 90 (HSP90)-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma (MCL) through transcriptomic reprogramming. We also showed that targeting CDK9 by AZD4573 and enitociclib is a safe and effective treatment in preclinical Mantle Cell Lymphoma (MCL) models, supporting CDK9 as a valid therapeutic target for MCL. However, current CDK9 inhibitors (CDK9is) under therapeutic development have room for improvement due to limited target selectivity and oral bioavailability. To this end, YX0798 was discovered to be a novel CDK9i through structural optimization. YX0798 demonstrated remarkable target selectivity and high affinity in binding to CDK9. Furthermore, YX0798 showed good oral bioavailability. YX0798, when administrated orally (5 mg\/kg daily), led to an efficacious antitumor activity in vivo and showed the potency in overcoming therapeutic resistance. Mechanistically, YX0798 downregulated the short-lived oncoprotein c-MYC and prosurvival protein myeloid cell leukemia sequence 1 (MCL-1) as a common mechanism of CDK9 inhibition. Moreover, YX0798 disrupted the cell cycle and resulted in transcriptomic reprogramming, eventually leading to cell death. Furthermore, YX0798 has the potential to be used in combination therapy with clinical agents to improve treatment efficacy. Together, these data demonstrate that YX0798 has oral bioavailability, exquisite selectivity, and antitumor potency that results from driving transcription reprogramming toward tumor cell killing.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016511","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T20:51:34Z","timestamp":1753131094000},"page":"4963-4976","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-4438","authenticated-orcid":false,"given":"Vivian","family":"Jiang","sequence":"first","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6625-704X","authenticated-orcid":false,"given":"Yu","family":"Xue","sequence":"additional","affiliation":[{"name":"2Chemical Biology Program, Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Kim","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianci","family":"Zhang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-5013","authenticated-orcid":false,"given":"Lei","family":"Nie","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McIntosh","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4321-0878","authenticated-orcid":false,"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"Chen","sequence":"additional","affiliation":[{"name":"2Chemical Biology Program, Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2811-1090","authenticated-orcid":false,"given":"Jia","family":"Zhou","sequence":"additional","affiliation":[{"name":"2Chemical Biology Program, Department of Pharmacology and Toxicology, The University of Texas Medical Branch, Galveston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9748-5486","authenticated-orcid":false,"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX"},{"name":"3Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"4","key":"2025101410264331900_bib1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41416-019-0648-6","article-title":"Principles and mechanisms of non-genetic resistance in cancer","volume":"122","author":"Bell","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"2025101410264331900_bib2","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"issue":"17","key":"2025101410264331900_bib3","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1093\/nar\/gkad666","article-title":"Deciphering a global source of non-genetic heterogeneity in cancer cells","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"7-8","key":"2025101410264331900_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1101\/gad.335679.119","article-title":"Structure and mechanism of the RNA polymerase II transcription machinery","volume":"34","author":"Schier","year":"2020","journal-title":"Genes Dev"},{"issue":"3","key":"2025101410264331900_bib5","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2022.12.006","article-title":"P-TEFb: the master regulator of transcription elongation","volume":"83","author":"Fujinaga","year":"2023","journal-title":"Mol Cell"},{"issue":"10","key":"2025101410264331900_bib6","doi-asserted-by":"crossref","first-page":"e54520","DOI":"10.15252\/embr.202154520","article-title":"CDK9 and PP2A regulate RNA polymerase II transcription termination and coupled RNA maturation","volume":"23","author":"Tellier","year":"2022","journal-title":"EMBO Rep"},{"issue":"14","key":"2025101410264331900_bib7","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1007\/s00018-021-03878-8","article-title":"CDK9 keeps RNA polymerase II on track","volume":"78","author":"Egloff","year":"2021","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2025101410264331900_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/21541264.2018.1523668","article-title":"CDK9: a signaling hub for transcriptional control","volume":"10","author":"Bacon","year":"2019","journal-title":"Transcription"},{"issue":"12","key":"2025101410264331900_bib9","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.cell.2021.04.022","article-title":"The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer","volume":"184","author":"Vervoort","year":"2021","journal-title":"Cell"},{"issue":"4","key":"2025101410264331900_bib10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/15384101.2016.1138186","article-title":"Overview of CDK9 as a target in cancer research","volume":"15","author":"Morales","year":"2016","journal-title":"Cell Cycle"},{"issue":"7","key":"2025101410264331900_bib11","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","article-title":"First-in-human dose-escalation study of cyclin-dependent kinase 9 inhibitor VIP152 in patients with advanced malignancies shows early signs of clinical efficacy","volume":"28","author":"Diamond","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025101410264331900_bib12","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/s41467-021-22872-z","article-title":"Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"2025101410264331900_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"issue":"491","key":"2025101410264331900_bib14","doi-asserted-by":"crossref","first-page":"eaau1167","DOI":"10.1126\/scitranslmed.aau1167","article-title":"Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Sci Transl Med"},{"issue":"1","key":"2025101410264331900_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-024-00484-9","article-title":"The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma","volume":"13","author":"Yan","year":"2024","journal-title":"Exp Hematol Oncol"},{"issue":"4","key":"2025101410264331900_bib16","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/1078-0432.CCR-19-1853","article-title":"AZD4573 is a highly selective CDK9 inhibitor that suppresses MCL-1 and induces apoptosis in hematologic cancer cells","volume":"26","author":"Cidado","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025101410264331900_bib17","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41375-022-01758-z","article-title":"VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia","volume":"37","author":"Sher","year":"2023","journal-title":"Leukemia"},{"issue":"15","key":"2025101410264331900_bib18","doi-asserted-by":"crossref","first-page":"11651","DOI":"10.1021\/acs.jmedchem.1c01000","article-title":"Changing for the better: discovery of the highly potent and selective CDK9 inhibitor VIP152 suitable for once weekly intravenous dosing for the treatment of cancer","volume":"64","author":"L\u00fccking","year":"2021","journal-title":"J Med Chem"},{"issue":"suppl 1","key":"2025101410264331900_bib19","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1182\/blood-2023-175035","article-title":"The selective CDK9 inhibitor VIP152 overcame therapeutic resistance in mantle cell Llymphoma","volume":"142","author":"Lee","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2025101410264331900_bib20","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J Med Chem"},{"issue":"7","key":"2025101410264331900_bib21","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/jm030644s","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening","volume":"47","author":"Halgren","year":"2004","journal-title":"J Med Chem"},{"issue":"2","key":"2025101410264331900_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1535-7163.MCT-18-0478","article-title":"Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma","volume":"18","author":"Li","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2025101410264331900_bib23","first-page":"1102","article-title":"PIK-75 overcomes venetoclax resistance via blocking PI3K-AKT signaling and MCL-1 expression in mantle cell lymphoma","volume":"12","author":"Huang","year":"2022","journal-title":"Am J Cancer Res"},{"issue":"24","key":"2025101410264331900_bib24","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1021\/acs.jmedchem.0c01754","article-title":"Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables short duration of target engagement for the treatment of hematological malignancies","volume":"63","author":"Barlaam","year":"2020","journal-title":"J Med Chem"},{"key":"2025101410264331900_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2015.10.025","article-title":"Men and mice: relating their ages","volume":"152","author":"Dutta","year":"2016","journal-title":"Life Sci"},{"key":"2025101410264331900_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13008-018-0040-6","article-title":"The functional diversity of Aurora kinases: a comprehensive review","volume":"13","author":"Willems","year":"2018","journal-title":"Cell Div"},{"issue":"4","key":"2025101410264331900_bib27","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cell.2005.02.001","article-title":"Mitochondria, oxidants, and aging","volume":"120","author":"Balaban","year":"2005","journal-title":"Cell"},{"issue":"8","key":"2025101410264331900_bib28","doi-asserted-by":"crossref","first-page":"793","DOI":"10.3390\/cells8080793","article-title":"Short overview of ROS as cell function regulators and their implications in therapy concepts","volume":"8","author":"Milkovic","year":"2019","journal-title":"Cells"},{"issue":"6","key":"2025101410264331900_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.freeradbiomed.2009.12.022","article-title":"Reactive oxygen species, cellular redox systems, and apoptosis","volume":"48","author":"Circu","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"2025101410264331900_bib30","doi-asserted-by":"crossref","first-page":"920161","DOI":"10.4061\/2010\/920161","article-title":"H2AX phosphorylation: its role in DNA damage response and cancer therapy","volume":"2010","author":"Podhorecka","year":"2010","journal-title":"J Nucleic Acids"},{"issue":"6","key":"2025101410264331900_bib31","first-page":"1143","article-title":"Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy","volume":"9","author":"Sedlacek","year":"1996","journal-title":"Int J Oncol"},{"key":"2025101410264331900_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-3-319-41342-6_9","article-title":"Potential use of flavopiridol in treatment of chronic diseases","volume":"929","author":"Srikumar","year":"2016","journal-title":"Adv Exp Med Biol"},{"issue":"12","key":"2025101410264331900_bib33","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1517\/13543780903418445","article-title":"Seliciclib in malignancies","volume":"18","author":"Aldoss","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"2025101410264331900_bib34","doi-asserted-by":"crossref","first-page":"e06535","DOI":"10.7554\/eLife.06535","article-title":"Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism","volume":"4","author":"Lu","year":"2015","journal-title":"Elife"},{"issue":"15","key":"2025101410264331900_bib35","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1128\/MCB.23.15.5165-5173.2003","article-title":"CDK9 is constitutively expressed throughout the cell cycle, and its steady-state expression is independent of SKP2","volume":"23","author":"Garriga","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2025101410264331900_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40364-024-00589-7","article-title":"The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomark Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4963\/2414894\/blooda_adv-2025-016511-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4963\/2414894\/blooda_adv-2025-016511-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:39:41Z","timestamp":1760452781000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4963\/546294\/YX0798-is-a-highly-potent-selective-and-orally"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":36,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016511","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.31.629756","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,30]]}}}